TSE:FRX Fennec Pharmaceuticals 8/13/2024 Earnings Report C$11.64 -0.34 (-2.84%) As of 07/18/2025 01:11 PM Eastern ProfileEarnings HistoryForecast Fennec Pharmaceuticals EPS ResultsActual EPS-C$0.27Consensus EPS C$0.08Beat/MissMissed by -C$0.35One Year Ago EPSN/AFennec Pharmaceuticals Revenue ResultsActual Revenue$9.94 millionExpected Revenue$18.67 millionBeat/MissMissed by -$8.73 millionYoY Revenue GrowthN/AFennec Pharmaceuticals Announcement DetailsQuarterDate8/13/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Fennec Pharmaceuticals Earnings HeadlinesFennec Pharmaceuticals Inc. (FENC) - Yahoo FinanceJune 27, 2025 | ca.finance.yahoo.comFennec Pharmaceuticals elects board members, shareholders approve proposalsJune 5, 2025 | investing.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.July 19 at 2:00 AM | American Alternative (Ad)Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comFennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comFennec reports Q4 EPS (6c), consensus (13c)March 10, 2025 | markets.businessinsider.comSee More Fennec Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fennec Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fennec Pharmaceuticals and other key companies, straight to your email. Email Address About Fennec PharmaceuticalsFennec Pharmaceuticals (TSE:FRX) Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.View Fennec Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)America Movil (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
